Skip to content
PubMed This is a summary of 35 peer-reviewed journal articles Updated
Nephrology · Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) and NPHLOP1

Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) / NPHLOP1: A Patient Guide

At a Glance

HHRH and NPHLOP1 are inherited phosphate-wasting disorders in which the kidneys lose too much phosphate, driving high urine calcium despite usually normal blood calcium. This can cause kidney stones and rickets or osteomalacia; oral phosphate is usually the main treatment.

Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) and NPHLOP1 are rare genetic conditions that fundamentally change how your kidneys manage minerals. At the heart of these conditions is a “leak” in the kidney’s filtration system, specifically involving the SLC34A3 or SLC34A1 genes. These genes provide the blueprints for transporters that are supposed to recapture phosphate from your urine and put it back into your blood. When they fail, phosphate spills out of the body, triggering a complex biological chain reaction that affects both your bones and your kidneys [1][2].

This mineral leak creates a unique and often confusing situation for patients and doctors alike. In most bone-thinning diseases, the body is starved for vitamin D, but in HHRH, the body does the opposite: it senses the low phosphate and overproduces the active form of vitamin D (calcitriol) to compensate. While this surge is meant to help, it backfires by forcing the gut to absorb massive amounts of calcium. Because the body cannot use this extra calcium without enough phosphate, the kidneys must flush it out. This high urinary calcium (hypercalciuria) is what leads to the two main complications of the disease: painful kidney stones and soft, mineral-starved bones known as rickets in children or osteomalacia in adults [1][3]. Your blood calcium level usually remains normal while this occurs.

Because HHRH and NPHLOP1 behave differently than more common bone conditions, the diagnosis is frequently missed or delayed. A standard blood test may show low phosphate, but evaluating renal phosphate handling alongside high levels of calcium in the urine is necessary for an accurate diagnosis. Distinguishing this from other types of rickets is essential, as the treatment for HHRH is fundamentally different from what is typically prescribed for other bone disorders. While many bone conditions require active vitamin D supplements, taking active vitamin D analogs for confirmed HHRH can worsen hypercalciuria and nephrocalcinosis [1][4]. If you are currently taking active vitamin D, do not stop or change it without first contacting your prescriber or metabolic-bone team.

Living with HHRH or NPHLOP1 means focusing on a precise and consistent treatment plan. The standard of care is generally oral phosphate supplementation, which helps replace the phosphate lost by the kidney and signals the body to reduce its overproduction of active vitamin D. While this therapy is the foundation of care, it requires individualized, clinician-directed monitoring of your blood and urine to protect your kidney health. By understanding the unique biology of your condition and avoiding treatments that could cause harm, you can work with your medical team to strengthen your bones and safeguard your kidneys for the future [5][3].

Common questions in this guide

What are HHRH and NPHLOP1?
They are rare inherited disorders in which the kidneys lose too much phosphate because of problems involving the SLC34A3 or SLC34A1 genes. The resulting mineral imbalance can cause high urine calcium, kidney stones, rickets in children, or osteomalacia in adults.
Why can HHRH cause kidney stones when my blood calcium is normal?
Low phosphate prompts the body to make more active vitamin D, which increases calcium absorption from the gut. The extra calcium is then passed into the urine, so blood calcium can stay normal while high urine calcium contributes to stones and calcium deposits in the kidneys.
Why is oral phosphate the usual treatment for HHRH or NPHLOP1?
Oral phosphate replaces some of the phosphate lost through the kidneys and helps signal the body to reduce its excess production of active vitamin D. Treatment is individualized and requires clinician-directed blood and urine monitoring to balance bone needs with kidney safety.
Could active vitamin D make HHRH worse?
In confirmed HHRH, active vitamin D analogs can increase high urine calcium and calcium deposits in the kidneys, so they may worsen the condition. Nutritional vitamin D and active vitamin D are different, and you should not stop or change any prescribed vitamin D without speaking with your prescriber.
How is HHRH or NPHLOP1 diagnosed?
Diagnosis requires more than finding low phosphate in the blood. Clinicians assess how the kidneys handle phosphate and check urine calcium, then consider the bone and kidney findings to distinguish these disorders from other types of rickets.
What symptoms can suggest HHRH or NPHLOP1?
Possible clues include persistent bone pain, muscle weakness, kidney stones, or a history of rickets or bowed legs in childhood. A family history of kidney stones or early-onset osteomalacia can also be important to share with a clinician.
Which specialists should manage HHRH or NPHLOP1?
Because these conditions affect phosphate balance, bones, and kidneys, care may involve a metabolic bone specialist and a nephrologist familiar with phosphate-wasting disorders. Your team can decide how often to check blood phosphate, urine calcium, and the kidneys for stones or calcium deposits.

Get notified when new evidence is published on nephrolithiasis/osteoporosis, hypophosphatemic.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (5)
  1. 1

    Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy.

    Bergwitz C, Miyamoto KI

    Pflugers Archiv : European journal of physiology 2019; (471(1)):149-163 doi:10.1007/s00424-018-2184-2.

    PMID: 30109410
  2. 2

    Renal phosphate handling and inherited disorders of phosphate reabsorption: an update.

    Wagner CA, Rubio-Aliaga I, Hernando N

    Pediatric nephrology (Berlin, Germany) 2019; (34(4)):549-559 doi:10.1007/s00467-017-3873-3.

    PMID: 29275531
  3. 3

    An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).

    Zhu Z, Bo-Ran Ho B, Chen A, et al.

    Kidney international 2024; (105(5)):1058-1076 doi:10.1016/j.kint.2024.01.031.

    PMID: 38364990
  4. 4

    Novel Variant of SLC34A3 in a Compound Heterozygous Brazilian Girl with Hereditary Hypophosphatemic Rickets with Hypercalciuria

    Valadares LP, de Carvalho DR

    Journal of clinical research in pediatric endocrinology 2025; (17(3)):326-331 doi:10.4274/jcrpe.galenos.2023.2023-5-2.

    PMID: 37680384
  5. 5

    Rickets guidance: part II-management.

    Haffner D, Leifheit-Nestler M, Grund A, Schnabel D

    Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.

    PMID: 35352187

This page explains HHRH and NPHLOP1 for educational purposes only and does not constitute medical advice. Do not start, stop, or change vitamin D or phosphate treatment without guidance from your prescriber or metabolic-bone team.